Understanding the mode of action of PDAC targeted drugs (P18)

• Subject Area: Gastroenterology
• Term: from 2018 to 2023
• Project identifier: Deutsche Forschungsgemeinschaft (DFG) - Project number 329628492

We will apply our newly developed proteomic technology termed decryptM that characterizes the effects of mutant KRAS targeted drugs on the proteome and phospho-proteome of cellular and animal models of PDAC in a fully time- and dose-dependent fashion. Covering 10,000 proteins, 20,000 phosphorylation sites, 2,000 acetylation sites and 5,000 ubiquitinylation sites in parallel will yield unprecedented pharmacodynamic information regarding drug target engagement, distinguish the main mechanism of action (MoA) from lesser drug effects, and shed light on drug adaptation or resistance mechanisms.

• DFG Programme: Collaborative Research Centres
• Subproject of: SFB 1321: Modelling and Targeting Pancreatic Cancer
• Applicant Institution: Technische Universität München (TUM)
• Project Head: Professor Dr. Bernhard Küster